Delving into the Latest Updates on Albendazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester, 5-(propylthio)-2-carbomethoxyaminobenzimidazole, Albendazole (JAN/USP/INN)

+ [11]

Target

Microtubule-associated proteins

Action

inhibitors

Mechanism

Microtubule-associated proteins inhibitors

Therapeutic Areas

Infectious DiseasesUrogenital DiseasesDigestive System Disorders

Active Indication

CystitisHelminthiasisIntestinal Diseases

Inactive Indication

EchinococcosisHIV InfectionsMicrosporidiosis+ [2]

Originator Organization-

Active Organization

Hubei Huazhong Pharmaceutical Co. Ltd.

GSK PlcGlaxoSmithKline KK

Inactive Organization

Smithkline Beecham

Impax Laboratories LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1984),

Helminthiasis

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC12H15N3O2S

InChIKeyHXHWSAZORRCQMX-UHFFFAOYSA-N

CAS Registry54965-21-8

Background (brief):
1. Burden:
Soil-transmitted helminth (STH) infections are a major public health problem, primarily affecting children. Although STH prevalence has decreased to 14% in Bangladesh, over 47 million preschool- and school-age children still live in high-risk areas.
2. Knowledge gap:
Albendazole shows 94-100% efficacy against A. lumbricoides but only 39-60% against T. trichuria. Ivermectin is also effective against hookworm and T. trichuria. Combining ivermectin with albendazole may be more effective than using either drug alone, but this combined therapy for STH has not yet been studied in Bangladesh.
3. Relevance:
STHs significantly impact children's nutrition, hindering health, growth, cognition, and learning. The national deworming program achieved 98.3% treatment coverage, but only 76.2% of PSAC were dewormed using self-prescribed medicines.
Hypothesis (if any):
The combination therapy of Albendazole and Ivermectin is more effective than Albendazole alone for treating soil-transmitted helminths in preschool-age children in Bangladesh
Objectives:
1. To compare the safety and efficacy of Albendazole and Ivermectin combination therapy with Albendazole monotherapy in preschool-aged children
2. To evaluate post-treatment egg reduction rates for various helminths at different time points
3. To determine the median time to re-infection following different anti-helminth interventions for various STH
Methods:
This Phase IIa single-blinded, randomized controlled trial will evaluate the safety and efficacy of ivermectin and albendazole combination therapy versus standard albendazole monotherapy for STH in 2-5 years in rural Belkuchi, Sirajganj. A total of 110 PSAC with confirmed STH will be randomly assigned to two treatment arms. Field activities and laboratory analysis will use the Kato-Katz technique for microscopic examination.
Outcome measures/variables:
* Evaluate the safety and efficacy of ivermectin and albendazole combination therapy for STH
* Evaluate the statistically significant impact on patient clinical outcomes, cure rate, and egg reduction rate
* Correlate changes in Cure Rate and Egg Reduction Rate for different STH at various time points

Start Date01 Jul 2025

Sponsor / Collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

[+1]

NCT06613997

/ Not yet recruitingPhase 3IIT

Randomized, Double-blind Trial Evaluating the Safety and Efficacy of a 21-day Course of Albendazole 400mg/Day in Subjects With High Loa Loa Microfilaremia

Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.

Start Date15 Jan 2025

Sponsor / Collaborator

Institut de Recherche pour le Développement

PACTR202411565966953

/ SuspendedNot Applicable

Open label, balanced, randomized, two-treatment, four-period, two-sequence, single oral dose, full replicate crossover, bioequivalence study of Albendazole Tablets IP 400 mg of Fidson with Zentel® Tablets 400 mg of GSK in healthy, adult male and female participants under fed conditions.

Start Date01 Jan 2025

Sponsor / Collaborator

Fidson Healthcare Plc

100 Clinical Results associated with Albendazole

Login to view more data

100 Translational Medicine associated with Albendazole

Login to view more data

100 Patents (Medical) associated with Albendazole

Login to view more data

10,452

Literatures (Medical) associated with Albendazole

01 Dec 2025·HISTOCHEMISTRY AND CELL BIOLOGY

The effects of benzimidazole and electrical stimulation on peripheral nerve regeneration after short- and long-term injury

Article

Author: Elhaj, Abubaker El ; Kaplan, Süleyman ; Elamin, Abdalla Ahmed Eldaw

Abstract:

This research investigated the effects of benzimidazole (BZ) and electrical stimulation (ES) on peripheral nerve regeneration after short- and long-term injury and assessed functional recovery by means of stereological, histological, and electrophysiological analyses. Fifty-four male albino Wistar rats were divided into nine groups of six animals each. No treatment or surgery was applied to the control (CONT) group. The sciatic nerve was crushed for 5 s in the short-term injury (STI) and for 60 s in the long-term injury (LTI) groups. In the STI + BZ group and the LTI + BZ group, the rats received 25 mg/kg/day of BZ via oral gavage for 28 days. In the STI + ES and LTI + ES groups, a 3-V current was applied for 20 min daily for 28 days. In the STI + BZ + ES group and the LTI + BZ + ES groups, 3-V ES was applied for 20 min per day for 28 days following oral administration of BZ at 25 mg/kg/day for 28 days. All groups were subjected to electrophysiological, electron microscopic, stereological, and statistical analyses. The stereological analyses revealed a significant increases in the numbers of myelinated axons in the STI + ES groups compared with the STI (p < 0.01). BZ treatment yielded no significant differences in the numbers of myelinated axons in the groups (p > 0.05). Histological evaluation of the STI and LTI groups showed that ES and BZ treatment positively affect the histological structure of the nerve.

01 Nov 2025·Current pediatric reviews

Pinworm (Enterobius Vermicularis) Infestation: An Updated Review

Article

Author: Wong, Alex H.C. ; Barankin, Benjamin ; Leung, Alexander K.C. ; Leong, Kin Fon ; Hon, Kam Lun ; Lam, Joseph M.

Background::

Pinworm infestation is an important public health problem worldwide, especially among children 5 to 10 years of age in developing countries with temperate climates. The problem is often overlooked because of its mild or asymptomatic clinical manifestations.

Objective::

The purpose of this article was to familiarize pediatricians with the diagnosis and management of pinworm infestation.

Methods::

A search was conducted in August 2023 in PubMed Clinical Queries using the key terms “Enterobius vermicularis,” OR “enterobiasis,” OR “pinworm.” The search strategy included all clinical trials, observational studies, and reviews published within the past 10 years. Only papers published in the English literature were included in this review. The information retrieved from the above search was used in the compilation of the present article.

Results::

Enterobiasis is a cosmopolitan parasitosis caused by Enterobius vermicularis. It affects approximately 30% of children worldwide and up to 60% of children in some developing countries. Predisposing factors include poor socioeconomic conditions, inadequate sanitation, poor personal hygiene, and overcrowding. Children aged 5 to 14 years have shown the highest prevalence of enterobiasis.. Egg transmission is mainly by the fecal-oral route. Approximately 30 to 40% of infested patients do not show any clinical symptoms of the disease. For symptomatic patients, the most common presenting symptom is nocturnal pruritus ani. The diagnosis of E. vermicularis infection is best established by the cellophane tape test. The sensitivity of one single test is around 50%; however, the sensitivity increases to approximately 90% with tests performed on three different mornings. If a worm is visualized in the perianal area or the stool, a pathological examination of the worm will yield a definitive diagnosis. As pinworms and eggs are not usually passed in the stool, examination of the stool is not recommended. The drugs of choice for the treatment of pinworm infestation are mebendazole (100 mg), pyrantel pamoate (11 mg/kg, maximum 1 g), and albendazole (400 mg), all of the above-mentioned drugs are given in a single dose and repeated in two weeks. Mebendazole and albendazole are both adulticidal and ovicidal, whereas pyrantel pamoate is only adulticidal. Given their safety and effectiveness, mebendazole and albendazole are currently the best available drugs for the treatment of pinworm infestation. For pregnant women, pyrantel is preferred to mebendazole and albendazole. Treatment of all household members should be considered, especially if there are multiple or repeated symptomatic infections because reinfection is common even when effective medication is given.

Conclusion::

In spite of effective treatment of pinworm infestation, recurrences are common. Recurrences are likely due to repeated cycles of reinfection (particularly, autoinfection) because of the short life span of adult pinworms. Good personal hygiene, such as frequent handwashing, especially after bowel movements and before meals, clipping of fingernails, avoidance of finger-sucking, nail-biting, and scratching in the anogenital area, are important preventive measures. Treatment of all household members should be considered, especially if there are multiple or repeated symptomatic infections.

01 Oct 2025·FOOD CHEMISTRY

Optimisation of supramolecular solvent microextraction of multiple benzimidazole from freshwater fish using RSM and ANN-GA methodology based on the comprehensive score M evaluated by the entropy weight method

Article

Author: Yang, Wuying ; Yan, Jiahui ; Geng, Xiang ; Xu, Qian ; Gao, Yanyan ; Xiong, Jianhua

In this study, a simple and efficient vortex-assisted supramolecular solvent microextraction (VA-SUPRA-ME) method for the simultaneous extraction of 8 BMZs from freshwater fish was established using response surface methodology (RSM) and artificial neural network genetic algorithm (ANN-GA) based on the comprehensive score M from the entropy weight method. The SUPRAS was added to the fish matrix and the benzimidazole extracted were determined by HPLC-PDA. The SUPRAS consisted of 2 mL n-decanol, 6 mL tetrahydrofuran and 32 mL water. The optimised extraction methods (425 μL SUPRAS, vortexing for 4.75 min and pH 6.5) were linearly good with correlation coefficients >0.9990. The recoveries ranged from 92.89 % to 112.29 %, with relative standard deviations (RSDs) of <6.4 %. The limits of detection (LODs) ranged from 0.005 to 0.010 mg kg^-1 and the limit of quantification (LOQs) from 0.017 to 0.033 mg kg^-1. This method offers faster extraction, lower solvent use and efficient multi-component extraction.

23

News (Medical) associated with Albendazole

21 May 2025

·pharma.economictimes.indiatimes.com

196 Drug Samples Fail CDSCO Quality Test; One Deca-Durabolin Sample Flagged as Spurious

New Delhi: Drug regulators, during their monthly quality review, have identified around 196 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” The drug alert issued by the Central Drugs Standard Control Organization ( CDSCO ) states that out of the 196 NSQ samples, 60 were identified by central drug laboratories, while the remaining 136 were flagged by state laboratories. In addition, one drug sample identified as spurious is a “ Nandrolone Decanoate Injection,” marketed as Deca-Durabolin —an anabolic steroid used for various medical conditions, including osteoporosis and anemia. According to a note from the Union Health Ministry , the spurious sample was picked from Bihar and “is manufactured by an unauthorized manufacturer using the brand name owned by another company.” In its alert, the CDSCO specified that the tested sample failed due to issues with the “Identification and Assay of Nandrolone Decanoate .” In India, “Deca-Durabolin 50 mg” is marketed by Ahmedabad-based Zydus Healthcare, following its acquisition of the brand from MSD (Merck Sharp & Dohme) in December 2016. The matter is currently under investigation, and the purported spurious drug is subject to the outcome of the inquiry. A drug is deemed spurious if it resembles another drug in a manner likely to deceive, or if it bears upon its label or container the name of another drug—among several other conditions detailed under Section 17-B of the Drugs and Cosmetics Act, 1940. Among the 60 NSQ samples flagged by central laboratories are Nimesulide and Paracetamol tablets manufactured by Pro-Pharma Care; Cefpodoxime Proxetil tablets by Sunvij Drugs; Ciprofloxacin tablets by Cadila Pharmaceuticals; and 57 other samples. The 136 NSQ samples identified by state laboratories include Glimepiride 1 mg and Metformin HCl 500 mg tablets manufactured by Surge Pharmaceuticals; Albendazole tablets by Samkem; and Oxfendazole and Ivermectin Bolus by Argon Remedies, among 133 other samples. The identification of drug samples as NSQ is based on the failure of the sample to meet one or more specified quality parameters. The term NSQ is defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. However, according to the Health Ministry, “the failure is specific to the drug products of the batch tested by the Government Laboratory and does not warrant concerns about other drug products available in the market.” The ministry added that the identification of NSQ and spurious medicines is undertaken regularly (monthly), in collaboration with state regulators, to ensure such drugs are detected and removed from the market. By Online Bureau ,

AcquisitionDrug Approval

21 May 2025

·pharma.economictimes.indiatimes.com

196 Drug Samples Fail CDSCO Quality Test; One Deca-Durabolin Sample Flagged as Spurious

New Delhi: Drug regulators, during their monthly quality review, have identified around 196 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” The drug alert issued by the Central Drugs Standard Control Organization ( CDSCO ) states that out of the 196 NSQ samples, 60 were identified by central drug laboratories, while the remaining 136 were flagged by state laboratories. In addition, one drug sample identified as spurious is a “ Nandrolone Decanoate Injection,” marketed as Deca-Durabolin —an anabolic steroid used for various medical conditions, including osteoporosis and anemia. According to a note from the Union Health Ministry , the spurious sample was picked from Bihar and “is manufactured by an unauthorized manufacturer using the brand name owned by another company.” In its alert, the CDSCO specified that the tested sample failed due to issues with the “Identification and Assay of Nandrolone Decanoate .” In India, “Deca-Durabolin 50 mg” is marketed by Ahmedabad-based Zydus Healthcare, following its acquisition of the brand from MSD (Merck Sharp & Dohme) in December 2016. The matter is currently under investigation, and the purported spurious drug is subject to the outcome of the inquiry. A drug is deemed spurious if it resembles another drug in a manner likely to deceive, or if it bears upon its label or container the name of another drug—among several other conditions detailed under Section 17-B of the Drugs and Cosmetics Act, 1940. Among the 60 NSQ samples flagged by central laboratories are Nimesulide and Paracetamol tablets manufactured by Pro-Pharma Care; Cefpodoxime Proxetil tablets by Sunvij Drugs; Ciprofloxacin tablets by Cadila Pharmaceuticals; and 57 other samples. The 136 NSQ samples identified by state laboratories include Glimepiride 1 mg and Metformin HCl 500 mg tablets manufactured by Surge Pharmaceuticals; Albendazole tablets by Samkem; and Oxfendazole and Ivermectin Bolus by Argon Remedies, among 133 other samples. The identification of drug samples as NSQ is based on the failure of the sample to meet one or more specified quality parameters. The term NSQ is defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. However, according to the Health Ministry, “the failure is specific to the drug products of the batch tested by the Government Laboratory and does not warrant concerns about other drug products available in the market.” The ministry added that the identification of NSQ and spurious medicines is undertaken regularly (monthly), in collaboration with state regulators, to ensure such drugs are detected and removed from the market. By Online Bureau ,

AcquisitionDrug Approval

18 Apr 2025

·pharma.economictimes.indiatimes.com

131 drugs fail CDSCO quality test, another Telma sample flagged as spurious

New Delhi: During the routine quality review check in March, a total of 131 drug samples failed to meet the quality standards, while one sample of the popular hypertension brand Telma 40 has been flagged as spurious. The monthly drug quality review alert issued by the Central Drugs Standard Control Organization (CDSCO) flagged 131 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” Making the announcement, the Union Health Ministry informed that of the total 131 NSQ samples, 70 were identified by the Central Drugs Laboratories and the remaining 61 samples were identified by the State Drugs Testing Laboratories. In addition to this, one drug sample flagged as spurious is of popular hypertension brand “Telma 40 (Telmisartan Tab I.P. 40mg),” manufactured in February 2024 and was plucked by the regulators from West Bengal. As per the Union Health Ministry, “the spurious sample was manufactured by an unauthorized manufacturer using a brand name owned by another company, and currently the matter is under investigation.” In its remark, the apex drug regulator CDSCO has said, “the product is purported to be spurious, however, the same is subject to the outcome of investigation.” Notably, last month a separate batch of the same brand picked from West Bengal was flagged as spurious. The sample was manufactured in 2022, and the reason for the drug test failure was notified as the sample “does not conform to I.P.” Telma (Telmisartan) is an angiotensin II receptor blocker that decreases high blood pressure and has been commercially marketed in India for the past two decades. The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 20 brands in the country, with a moving annual total (MAT) value of around ₹483 crore. The NSQ drug samples flagged by the central drug laboratories in March include Pantoprazole manufactured by Kolkata-based Shangrila Industries; Albendazole tablets by Mumbai-based Digital Vision; Telmisartan tablets manufactured by Guwahati-based Swiss Garnier Life Sciences; among 67 others. While the NSQ samples identified by state drug testing laboratories include Norfloxacin tablets manufactured by Revat Laboratories; Glimepiride tablets by Kerala State Drugs and Pharmaceuticals; Sucralfate by Legend Industries; among 58 others. Under Section 17-B of the Drugs and Cosmetics Act, 1940, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; an imitation of, or a substitute for, another drug; resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among several other provisions. For NSQ samples, the drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Online Bureau ,

100 Deals associated with Albendazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00134	Albendazole	P02CA03	DB00518

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Echinococcosis	United States	Impax Laboratories LLC	11 Jun 1996
Neurocysticercosis	United States	Impax Laboratories LLC	11 Jun 1996
Cystitis	Japan	GlaxoSmithKline KK	19 Jan 1994
Helminthiasis	China	Hubei Huazhong Pharmaceutical Co. Ltd.	01 Jan 1984

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	United States	Smithkline Beecham	31 Aug 2001
Microsporidiosis	Phase 3	United States	Smithkline Beecham	31 Aug 2001
Protozoan Infections	Phase 3	United States	Smithkline Beecham	31 Aug 2001
Intestinal Diseases	Phase 1	India	GSK Plc	21 Aug 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


S19.010 (AAN2025)	Not Applicable	Neurocysticercosis	320	Albendazole-Praziquantel combined therapy	ejmdyrmvzk(beonjphhmo): OR = 1.4 (95% CI, 0.72 - 2.72), P-Value = 0.30 View more	Positive	07 Apr 2025
				Albendazole monotherapy
NCT06201559 (CTgov)	Phase 1	Intestinal Diseases	70	Albendazole (Albendazole IP 400 mg/400mg - Test 1 (T1))	tvqzqifgev(zgzzbgwnzz) = qlkeiqxbpb bptoebdill (ptiezqihku, 114.1) View more	-	27 Jan 2025
				Albendazole (Albendazole IP 400 mg/400 mg - Test 2 (T2))	tvqzqifgev(zgzzbgwnzz) = rfyqzouufh bptoebdill (ptiezqihku, 110.9) View more
NCT04700423 (CTgov)	Phase 2/3	Trichuriasis \| Hookworm Infections \| Ascariasis ... View more	536	albendazole+moxidectin (A: Moxidectin (8 mg) / Albendazole (400 mg))	rrjedmzhvo(mqhyczcsxa) = zfjlfodzxa miovraffud (seaoxitirp, quqkstleld - zscpwpkgfs) View more	-	05 Dec 2024
				albendazole+ivermectin (B: Ivermectin (200 µg/kg) / Albendazole (400 mg))	rrjedmzhvo(mqhyczcsxa) = onhpgabhop miovraffud (seaoxitirp, shaytdkwbf - ssisiwposb) View more
NCT04326868 (Pubmed \| Antimicrob Agents Chemother)	Phase 4	Infectious Diseases	-	Albendazole 400 mg	euczblquqz(uidkaxsuzi) = xmlidfbyyg cfighbrgmn (whqqjojbme, 58 - 81) View more	-	02 Apr 2024
NCT03527732 (CTgov)	Phase 2/3	Trichuriasis	1,673	Albendazole (Albendazole in Côte d'Ivoire)	klsdltddnr(xfvgccdipi) = wmauvwmhtk kygjxahlvv (rfhqtbmfnf, hkbtnmthzf - hgesyhilyw) View more	-	20 Mar 2024
				Albendazole+Ivermectin (Albendazole and Ivermectin in Côte d'Ivoire)	klsdltddnr(xfvgccdipi) = ncvtdhzial kygjxahlvv (rfhqtbmfnf, emihtwmdlo - csuohumakx) View more
PACTR202202738940158 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Hookworm Infections	225	Dual-dose albendazole	gxclvghurj(mdkvdihhyt) = vdgukiuome ptvzawnocj (dsrwasntoa, 90.9 - 99) View more	-	03 Jul 2023
				Single-dose albendazole	gxclvghurj(mdkvdihhyt) = vriiobwojg ptvzawnocj (dsrwasntoa, 75.7 - 90.2) View more
NCT04726969 (CTgov)	Phase 3	Trichuriasis \| Ascariasis \| Hookworm Infections	255	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin and Albendazole)	lppyvmqfvt = rihxzynwsl xdnednndkc (ljlzuprsqs, mlczkoovdw - aoyazlcdqb) View more	-	02 Feb 2023
				Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	lppyvmqfvt = brekfgqzqr xdnednndkc (ljlzuprsqs, dyyqzimivj - rrbdnrunfj) View more
NCT02899936 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Elephantiasis, Filarial	23,789	Albendazole + Diethylcarbamazine + Ivermectin	cocpnzlxsn(vmlcjjnntv) = The overall frequency of AEs were similar after either DA (18%) or IDA (20%) treatment jedclmvvjy (qhnencaxdz ) View more	Positive	09 Feb 2022
				Diethylcarbamazine + Albendazole
EANM2021	Not Applicable	Alveolar Echinococcosis FDG-uptake	47	Benzimidazole therapy successfully stopped	hyxpcgsgde(yyptelzsbm) = ygaahxaxce tmzoikywmt (vxwxnermtw, 766 - 2517)	-	24 Sep 2021
NCT03527732 (Pubmed \| PLoS Negl Trop Dis)	Phase 2/3	Helminthiasis	1,673	Ivermectin-albendazole	jiocdogykj(wxfkwkhzug) = obcppxcgmx pdjswxnuur (bqzmgqbnkj ) View more	-	30 Jun 2021
				Albendazole	jiocdogykj(wxfkwkhzug) = phgfdplmxi pdjswxnuur (bqzmgqbnkj ) View more